Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Invivyd's monoclonal antibody (mAb) VYD2311 is a prophylactic for COVID has greater efficacy and less side effects than COVID vaccines. The current administration's clear goal of minimizing the ...
The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash ...
Interim data captured from a phase 3 trial suggest pemivibart may be effective prophylaxis against COVID-19 infection for high-risk patients with significant immunocompromising conditions who continue ...
Most people have put the COVID-19 pandemic behind them. Infections, vaccinations, or a combination of both have bolstered people's immunity, and while new variants continue to pop up, getting sick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback